BR112023024968A2 - Tratamento da obesidade e distúrbios relacionados à obesidade - Google Patents
Tratamento da obesidade e distúrbios relacionados à obesidadeInfo
- Publication number
- BR112023024968A2 BR112023024968A2 BR112023024968A BR112023024968A BR112023024968A2 BR 112023024968 A2 BR112023024968 A2 BR 112023024968A2 BR 112023024968 A BR112023024968 A BR 112023024968A BR 112023024968 A BR112023024968 A BR 112023024968A BR 112023024968 A2 BR112023024968 A2 BR 112023024968A2
- Authority
- BR
- Brazil
- Prior art keywords
- obesity
- treatment
- related disorders
- peptide
- glp
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 7
- 235000020824 obesity Nutrition 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract 2
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 abstract 1
- 101150020692 Gipr gene Proteins 0.000 abstract 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21178712 | 2021-06-10 | ||
| PCT/EP2022/065826 WO2022258805A1 (en) | 2021-06-10 | 2022-06-10 | Treatment of obesity and obesity-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024968A2 true BR112023024968A2 (pt) | 2024-02-20 |
Family
ID=76502668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024968A BR112023024968A2 (pt) | 2021-06-10 | 2022-06-10 | Tratamento da obesidade e distúrbios relacionados à obesidade |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240277813A1 (enExample) |
| EP (1) | EP4351630A1 (enExample) |
| JP (1) | JP2024521398A (enExample) |
| KR (1) | KR20240021212A (enExample) |
| CN (1) | CN117881415A (enExample) |
| AU (1) | AU2022289247A1 (enExample) |
| BR (1) | BR112023024968A2 (enExample) |
| CA (1) | CA3221661A1 (enExample) |
| IL (1) | IL309128A (enExample) |
| MX (1) | MX2023014740A (enExample) |
| WO (1) | WO2022258805A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| KR20260118441A (ko) | 2023-11-21 | 2026-07-30 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용 |
| KR20250095833A (ko) * | 2023-12-19 | 2025-06-27 | 한미약품 주식회사 | 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2026046202A1 (zh) * | 2024-08-26 | 2026-03-05 | 博瑞生物医药（苏州）股份有限公司 | Glp-1/gip肽或含有其的药物组合物的用途 |
| KR102966075B1 (ko) * | 2024-11-19 | 2026-05-19 | (주)케어젠 | 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2597649A1 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US12187773B2 (en) * | 2018-12-03 | 2025-01-07 | Antag Therapeutics Aps | Modified GIP peptide analogues |
| CN122520749A (zh) * | 2019-12-03 | 2026-08-07 | 安泰博医药 | 优化的gip肽类似物 |
-
2022
- 2022-06-10 MX MX2023014740A patent/MX2023014740A/es unknown
- 2022-06-10 BR BR112023024968A patent/BR112023024968A2/pt unknown
- 2022-06-10 KR KR1020247000556A patent/KR20240021212A/ko active Pending
- 2022-06-10 EP EP22733387.9A patent/EP4351630A1/en active Pending
- 2022-06-10 IL IL309128A patent/IL309128A/en unknown
- 2022-06-10 JP JP2023575695A patent/JP2024521398A/ja active Pending
- 2022-06-10 US US18/565,984 patent/US20240277813A1/en active Pending
- 2022-06-10 AU AU2022289247A patent/AU2022289247A1/en active Pending
- 2022-06-10 WO PCT/EP2022/065826 patent/WO2022258805A1/en not_active Ceased
- 2022-06-10 CA CA3221661A patent/CA3221661A1/en active Pending
- 2022-06-10 CN CN202280040922.8A patent/CN117881415A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4351630A1 (en) | 2024-04-17 |
| WO2022258805A1 (en) | 2022-12-15 |
| US20240277813A1 (en) | 2024-08-22 |
| KR20240021212A (ko) | 2024-02-16 |
| CN117881415A (zh) | 2024-04-12 |
| JP2024521398A (ja) | 2024-05-31 |
| AU2022289247A1 (en) | 2023-12-21 |
| IL309128A (en) | 2024-02-01 |
| CA3221661A1 (en) | 2022-12-15 |
| MX2023014740A (es) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014740A (es) | Tratamiento de la obesidad y trastornos relacionados con la obesidad. | |
| SA521421080B1 (ar) | مركبات مساعدة مشتركة البولي ببتيد المفرزة للإنسولين المعتمدة على الجلوكوز/ الببتيد-1 الشبيه بجلوكاجون | |
| BR112023003668A2 (pt) | Agonistas duplos de glp-1/gip | |
| BR112022025615A2 (pt) | Agonistas duplos de glp-1/gip de ação prolongada | |
| ECSP17043648A (es) | Compuestos co-agonistas de gip y glp-1 | |
| BR112021020071A2 (pt) | Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos | |
| AR084558A1 (es) | Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1) | |
| CO2025001430A2 (es) | Agonista dual de glp-1/gip, método de preparación y uso del mismo | |
| MX2021005725A (es) | Tratamiento de la obesidad y sus complicaciones. | |
| MX2026000195A (es) | Triagonista de los receptores glp-1, gip y gcg y su uso | |
| MX2024002600A (es) | Regimen de dosificacion. | |
| DK3406264T3 (da) | Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf | |
| ECSP23019850A (es) | Agonistas duales glp-1/gip | |
| EA202092891A1 (ru) | Соединения-коагонисты gip/glp1 | |
| TH2101000319A (th) | สารประกอบอะโกนิสท์ร่วม gip/glp1 |